Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung

Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Nonsquamous Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Resectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms, Neoplasms

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Advanced Non-small Cell Lung Cancer

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Squamous-Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

CEMI-LUNG

SYS6090 Combination Therapy in Advanced Lung Cancer

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Acclaim-1

ATLAS

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)

LUNAR-2

BRIDGE

LungTime-C02

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants

Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

LUCACRIMUNO

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

Gut Microbiota Reconstruction for NSCLC Immunotherapy

SQUINT

A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer

Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung